All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AM3101
Therapeutic Area: Musculoskeletal Product Name: AM3101
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Photon Fund
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 25, 2021
Details:
The proceeds from the financing will enable Amplicore to complete the preclinical development of its two leading products, AM3101 and AM1101, and position the company for the next round of financing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Diclofenac Epolamine
Therapeutic Area: Musculoskeletal Product Name: Epoladerm
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Virpax Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2021
Details:
Under the terms of this agreement, Charles River Laboratories will perform seven preclinical animal studies including method, dosage, and toxicity as part of the required the U.S. FDA enabling trials for an Investigational New Drug Application for Epoladerm.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Micronized umbilical cord tissue
Therapeutic Area: Musculoskeletal Product Name: Signature Cord Prime
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
U.S. Food and Drug Administration (FDA) has approved an IND Application to proceed with the study of Signature Cord Prime™ in patients with symptomatic osteoarthritis (OA) of the knee with our Principal Investigator.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Parathyroid Hormone
Therapeutic Area: Musculoskeletal Product Name: PTH
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $69.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing December 10, 2020
Details:
Rani Therapeutics platform technology converts injectable drugs like PTH and adalimumab into pills. Rani has conducted early human studies with adalimumab and exenatide to confirm high bioavailability with the Rani delivery approach.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KER-012
Therapeutic Area: Musculoskeletal Product Name: KER-012
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
In Preclinical Studies, KER-012 Increased Trabecular Bone by Reducing Bone Catabolism and Enhancing Anabolism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Calcium Alpha-Ketoglutarate
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The multi-year study, conducted by the Buck Institute for Research on Aging in aged mice, found that calcium alpha-ketoglutarate (Ca-AKG), a stable form of alpha-ketoglutarate, promotes longer, healthier life associated with a decrease in levels of inflammatory cytokines.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
